BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 38055384)

  • 1. Are both distinct epithelial and stromal cells molecular analysis from phyllodes tumors versus fibroadenoma components affected in breast fibroepithelial progression?
    Waitzberg ÂFL; Ferreira ENE; Pinilla M; Pineda P; Malinverni ACM; Soares FA; Carraro DM
    Acta Cir Bras; 2023; 38():e386823. PubMed ID: 38055384
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutational analysis of MED12 exon 2 in a spectrum of fibroepithelial tumours of the breast: implications for pathogenesis and histogenesis.
    Lien HC; Huang CS; Yang YW; Jeng YM
    Histopathology; 2016 Feb; 68(3):433-41. PubMed ID: 26109290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutational analysis of MED12 in fibroadenomas and phyllodes tumors of the breast by means of targeted next-generation sequencing.
    Mishima C; Kagara N; Tanei T; Naoi Y; Shimoda M; Shimomura A; Shimazu K; Kim SJ; Noguchi S
    Breast Cancer Res Treat; 2015 Jul; 152(2):305-12. PubMed ID: 26093648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MED12 somatic mutations in fibroadenomas and phyllodes tumours of the breast.
    Piscuoglio S; Murray M; Fusco N; Marchiò C; Loo FL; Martelotto LG; Schultheis AM; Akram M; Weigelt B; Brogi E; Reis-Filho JS
    Histopathology; 2015 Nov; 67(5):719-29. PubMed ID: 25855048
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MED12 exon 2 and TERT promoter mutations in primary and recurrent breast fibroepithelial lesions.
    Hu Y; Li G; Wang L; Zhang L; Guan J; Wang J
    Pathol Int; 2021 Dec; 71(12):814-822. PubMed ID: 34597441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recurrent
    Pareja F; Da Cruz Paula A; Murray MP; Hoang T; Gularte-Mérida R; Brown D; da Silva EM; Sebastiao APM; Giri DD; Weigelt B; Reis-Filho JS; Brogi E
    J Clin Pathol; 2019 Mar; 72(3):258-262. PubMed ID: 30467240
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distribution of MED12 mutations in fibroadenomas and phyllodes tumors of the breast--implications for tumor biology and pathological diagnosis.
    Pfarr N; Kriegsmann M; Sinn P; Klauschen F; Endris V; Herpel E; Muckenhuber A; Jesinghaus M; Klosterhalfen B; Penzel R; Lennerz JK; Weichert W; Stenzinger A
    Genes Chromosomes Cancer; 2015 Jul; 54(7):444-52. PubMed ID: 25931199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Periductal Stromal Tumor of the Breast with a
    Anderson B; Marotti JD; Lefferts JA; Muller KE
    Int J Surg Pathol; 2023 Dec; 31(8):1626-1631. PubMed ID: 36823780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stromal
    da Silva EM; Beca F; Sebastiao APM; Murray MP; Silveira C; Da Cruz Paula A; Pareja F; Wen HY; D'Alfonso TM; Edelweiss M; Weigelt B; Brogi E; Reis-Filho JS; Zhang H
    J Clin Pathol; 2022 Feb; 75(2):133-136. PubMed ID: 33376197
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Droplet-digital PCR reveals frequent mutations in TERT promoter region in breast fibroadenomas and phyllodes tumours, irrespective of the presence of MED12 mutations.
    Otsuji K; Sasaki T; Tanabe M; Seto Y
    Br J Cancer; 2021 Jan; 124(2):466-473. PubMed ID: 33046803
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Massively parallel sequencing of phyllodes tumours of the breast reveals actionable mutations, and TERT promoter hotspot mutations and TERT gene amplification as likely drivers of progression.
    Piscuoglio S; Ng CK; Murray M; Burke KA; Edelweiss M; Geyer FC; Macedo GS; Inagaki A; Papanastasiou AD; Martelotto LG; Marchio C; Lim RS; Ioris RA; Nahar PK; Bruijn ID; Smyth L; Akram M; Ross D; Petrini JH; Norton L; Solit DB; Baselga J; Brogi E; Ladanyi M; Weigelt B; Reis-Filho JS
    J Pathol; 2016 Mar; 238(4):508-18. PubMed ID: 26832993
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic differences between benign phyllodes tumors and fibroadenomas revealed through targeted next generation sequencing.
    Ng CCY; Md Nasir ND; Loke BN; Tay TKY; Thike AA; Rajasegaran V; Liu W; Lee JY; Guan P; Lim AH; Chang KTE; Gudi MA; Madhukumar P; Tan BKT; Tan VKM; Wong CY; Yong WS; Ho GH; Ong KW; ; Yip GWC; Bay BH; Tan P; Teh BT; Tan PH
    Mod Pathol; 2021 Jul; 34(7):1320-1332. PubMed ID: 33727697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frequent MED12 mutations in phyllodes tumours of the breast.
    Yoshida M; Sekine S; Ogawa R; Yoshida H; Maeshima A; Kanai Y; Kinoshita T; Ochiai A
    Br J Cancer; 2015 May; 112(10):1703-8. PubMed ID: 25839987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estrogen receptor-beta is expressed in stromal cells of fibroadenoma and phyllodes tumors of the breast.
    Sapino A; Bosco M; Cassoni P; Castellano I; Arisio R; Cserni G; Dei Tos AP; Fortunati N; Catalano MG; Bussolati G
    Mod Pathol; 2006 Apr; 19(4):599-606. PubMed ID: 16554735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MED12 exon 2 mutations in phyllodes tumors of the breast.
    Nagasawa S; Maeda I; Fukuda T; Wu W; Hayami R; Kojima Y; Tsugawa K; Ohta T
    Cancer Med; 2015 Jul; 4(7):1117-21. PubMed ID: 25865354
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MED12 protein expression in breast fibroepithelial lesions: correlation with mutation status and oestrogen receptor expression.
    Tan WJ; Chan JY; Thike AA; Lim JC; Md Nasir ND; Tan JS; Koh VC; Lim WK; Tan J; Ng CC; Rajasegaran V; Nagarajan S; Bay BH; Teh BT; Tan PH
    J Clin Pathol; 2016 Oct; 69(10):858-65. PubMed ID: 27056456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MED12, TERT promoter and RBM15 mutations in primary and recurrent phyllodes tumours.
    Garcia-Dios DA; Levi D; Shah V; Gillett C; Simpson MA; Hanby A; Tomlinson I; Sawyer EJ
    Br J Cancer; 2018 Jan; 118(2):277-284. PubMed ID: 29315289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genomic characterisation of breast fibroepithelial lesions in an international cohort.
    Md Nasir ND; Ng CCY; Rajasegaran V; Wong SF; Liu W; Ng GXP; Lee JY; Guan P; Lim JQ; Thike AA; Koh VCY; Loke BN; Chang KTE; Gudi MA; Lian DWQ; Madhukumar P; Tan BKT; Tan VKM; Wong CY; Yong WS; Ho GH; Ong KW; ; Tan P; Teh BT; Tan PH
    J Pathol; 2019 Dec; 249(4):447-460. PubMed ID: 31411343
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TERT promoter mutations are frequent and show association with MED12 mutations in phyllodes tumors of the breast.
    Yoshida M; Ogawa R; Yoshida H; Maeshima A; Kanai Y; Kinoshita T; Hiraoka N; Sekine S
    Br J Cancer; 2015 Oct; 113(8):1244-8. PubMed ID: 26355235
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MED12 mutations in breast phyllodes tumors: evidence of temporal tumoral heterogeneity and identification of associated critical signaling pathways.
    Laé M; Gardrat S; Rondeau S; Richardot C; Caly M; Chemlali W; Vacher S; Couturier J; Mariani O; Terrier P; Bièche I
    Oncotarget; 2016 Dec; 7(51):84428-84438. PubMed ID: 27806318
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.